Gemcitabine and platinum combinations in pancreatic cancer

Cancer

Volumn 95, Issue 4 SUPPL., 2002, Pages 908-911

  Philip, Agop ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Cisplatin; Gemcitabine; Myelosuppression; Pancreatic cancer; Phase II studies

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PLATINUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; FEVER; HUMAN; NEUTROPENIA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0037103046     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10757     Document Type: Conference Paper

References (25)

1. Cancer statistics, 2001
2. Cancer of the pancreas
3. Prognostic indicators for survival after resection of pancreatic adenocarcinoma
4. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas
5. Phase II study of gemcitabine in patients with advanced pancreatic cancer
6. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
7. Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small cell lung cancer
8. Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: A phase II study
9. Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: A Hoosier Oncology Group sudy
10. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer
11. Rationale of a phase III study comparing a standard cisplatin regimen (mitomycin/ifosfamide/cisplatin) with cisplatin and gemcitabine in non-small cell lung cancer
12. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model
13. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines
14. Activity of cisplatin in adenocarcinoma of the pancreas
15. Pre-clinical combination therapy with gemcitabine and mechanisms of resistance
16. Gemcitabine in cisplatin-resistant ovarian cancer
17. Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer
18. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer
19. Randomized trial of gemcitabine (GEM) alone or with cisplatin (CDDP) in the treatment of advanced pancreatic cancer: A phase II multicenter study of the Southern Italy Oncology Group
20. Gemcitabine: Preclinical pharmacology and mechanisms of action
21. Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer
22. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines
23. Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: A preliminary report
24. Gemcitabine-oxaliplatin (GEMOX) combination in advanced pancreatic carcinoma (APC): A Gercor multicenter phase II study
25. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma